MX2009011925A - Tratamiento de enfermedad cardiovascular y dislipidemia con el uso de inhibidores de secrecion de fosfolipasa a2 y terapias en combinacion de inhibidores de fosfolipasa. - Google Patents
Tratamiento de enfermedad cardiovascular y dislipidemia con el uso de inhibidores de secrecion de fosfolipasa a2 y terapias en combinacion de inhibidores de fosfolipasa.Info
- Publication number
- MX2009011925A MX2009011925A MX2009011925A MX2009011925A MX2009011925A MX 2009011925 A MX2009011925 A MX 2009011925A MX 2009011925 A MX2009011925 A MX 2009011925A MX 2009011925 A MX2009011925 A MX 2009011925A MX 2009011925 A MX2009011925 A MX 2009011925A
- Authority
- MX
- Mexico
- Prior art keywords
- spla2
- cvd
- inhibitors
- treatment
- administration
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 9
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 3
- 208000017170 Lipid metabolism disease Diseases 0.000 title abstract 3
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 title abstract 3
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 6
- 208000037998 chronic venous disease Diseases 0.000 abstract 6
- 230000007423 decrease Effects 0.000 abstract 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000007505 plaque formation Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se ha descubierto que la administración de inhibidores secretorios de fosfolipasa A2 (SPLA2) disminuye los niveles de colesterol, la formación de placas ateroscleróticas y el aneurisma aórtico en ratones y que disminuye los niveles de colesterol y triglicéridos en los seres humanos; crecientemente, se ha descubierto que la administración de inhibidores de SPLA2 disminuye los niveles de colesterol, incluso cuando se administraron inhibidores una vez al día; por lo tanto, se proveen en la presente métodos de tratar dislipidemia, CVD y afecciones asociadas con CVD, tales como aterosclerosis y síndrome metabólico, administrando uno o más inhibidores de SPLA2 significantemente, la administración de inhibidores de SPLA2 y varios compuestos usados en el tratamiento de CVD, tales como por ejemplo estatinas, resultaron en mayores disminuciones de los niveles de LDL y de partículas de LDL de manera sinérgica; además, la administración de inhibidores de SPLA2 y estatinas resultó en una disminución sinérgica del contenido de placas; por lo tanto, se proveen también en la presente composiciones que comprenden uno o más inhibidores de SPLA2 y uno o más compuestos usados en el tratamiento de CVD, tales como por ejemplo estatinas, y métodos de usar estas composiciones para tratar dislipidemia CVD y afecciones asociadas con CVD, tales como aterosclerosis y síndrome metabólico.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91591007P | 2007-05-03 | 2007-05-03 | |
| US96959107P | 2007-08-31 | 2007-08-31 | |
| US19004407P | 2007-10-18 | 2007-10-18 | |
| PCT/US2008/062577 WO2008137803A1 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011925A true MX2009011925A (es) | 2010-06-25 |
Family
ID=42263481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011925A MX2009011925A (es) | 2007-05-03 | 2008-05-02 | Tratamiento de enfermedad cardiovascular y dislipidemia con el uso de inhibidores de secrecion de fosfolipasa a2 y terapias en combinacion de inhibidores de fosfolipasa. |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20100109840A (es) |
| IL (1) | IL201897A0 (es) |
| MX (1) | MX2009011925A (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250014832A (ko) * | 2023-07-21 | 2025-02-03 | 현대약품 주식회사 | 약학 조성물 및 이의 제조 방법 |
-
2008
- 2008-05-02 MX MX2009011925A patent/MX2009011925A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025139A patent/KR20100109840A/ko not_active Withdrawn
-
2009
- 2009-11-03 IL IL201897A patent/IL201897A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL201897A0 (en) | 2010-06-16 |
| KR20100109840A (ko) | 2010-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501131A1 (en) | Composition for treating hyperlipidemia comprising oxytomodulin derivative | |
| EP4403213A3 (en) | Methods for reducing cardiovascular risk | |
| MY187464A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester | |
| IL197080A0 (en) | Pyrimidone compounds as gsk-3 inhibitors | |
| UA95310C2 (ru) | Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака | |
| MX2018005096A (es) | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| TW200738710A (en) | Tricyclic inhibitors of 5-lipoxygenase | |
| MX2012011380A (es) | Compuestos aromaticos multisustituidos como inhibidores de trombina. | |
| WO2010003127A3 (en) | Antagonists of prostaglandin d2 receptors | |
| MX2016002178A (es) | Composiciones y metodos terapeuticos para la regresion acelerada de placa. | |
| MX2010001565A (es) | Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90. | |
| WO2009108720A3 (en) | Antagonists of prostaglandin d2 receptors | |
| MX2009008547A (es) | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. | |
| WO2009145989A3 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
| PH12013502370A1 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| MX2009011925A (es) | Tratamiento de enfermedad cardiovascular y dislipidemia con el uso de inhibidores de secrecion de fosfolipasa a2 y terapias en combinacion de inhibidores de fosfolipasa. | |
| NO20083641L (no) | Dibenzylaminforbindelser, samt derivater derav | |
| WO2009037705A3 (en) | Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation | |
| EA200971020A1 (ru) | Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |